HDAC11
HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.
Overview
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes.
Open Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.93, genetic association 0.38, clinical 0.95).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.
- 1 · What it is
HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.
- 2 · What goes wrong in cancer
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4).
- 3 · How drugs use it
No product in this corpus aims at HDAC11 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:19086 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96DB2 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000163517 (association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: plasma cell myeloma 0.55, non-Hodgkin lymphoma 0.56, skin cancer 0.56 (GraphQL API, CC0))
Biology
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Location: Nucleus (UniProt). Locus 3p25.1 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
- Multiple myeloma: Open Targets association 0.55 with plasma cell myeloma (MONDO_0009693)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.95. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"HDAC11" OR ABSTRACT:"HDAC11" OR TITLE:"histone deacetylase 11" OR ABSTRACT:"histone deacetylase 11" OR TITLE:"Histone deacetylase 11" OR ABSTRACT:"Histone deacetylase 11") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HDAC11, not a curated reading list.